Characteristics and Progression of Preclinical Inflammatory Bowel Disease.

Related Articles Characteristics and Progression of Preclinical Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2017 Nov 10;: Authors: Rodríguez-Lago I, Merino O, Azagra I, Maiz A, Zapata E, Higuera R, Montalvo I, Fernández-Calderón M, Arreba P, Carrascosa J, Iriarte A, Portillo I, Aguirre U, Barreiro-de Acosta M, Muñoz-Navas M, Cabriada JL Abstract BACKGROUND & AIMS: Inflammatory bowel disease (IBD) is a chronic disease usually diagnosed after the appearance of gastrointestinal symptoms. Little is known about IBD progression during its early and even preclinical phases. We aimed to determine the number of…

Read More

Clinical and pharmacokinetic factors associated with adalimumab-induced mucosal healing in patients with Crohn’s disease.

Related Articles Clinical and pharmacokinetic factors associated with adalimumab-induced mucosal healing in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2017 Nov 02;: Authors: Watanabe K, Matsumoto T, Hisamatsu T, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T, DIAMOND study group Abstract BACKGROUND & AIMS: We previously reported results from a prospective randomized controlled trial comparing the efficacy of adalimumab monotherapy vs combination with azathioprine for patients with Crohn’s…

Read More

Increasing Prescription of Opiates and Mortality in Patients with Inflammatory Bowel Diseases in England.

Related Articles Increasing Prescription of Opiates and Mortality in Patients with Inflammatory Bowel Diseases in England. Clin Gastroenterol Hepatol. 2017 Oct 24;: Authors: Burr NE, Smith C, West R, Hull MA, Subramanian V Abstract BACKGROUND & AIMS: The prescription of opiate medications is increasing. Individuals with inflammatory bowel diseases (IBD) can develop serious complications from opiate use, but few data are available on the prescription of these drugs to patients with IBD. We examined trends in prescriptions of opiates and their association with all-cause mortality in individuals with IBD. METHODS:…

Read More

Patient-Reported Outcome Measures for Use in Clinical Trials and Clinical Practice in Inflammatory Bowel Diseases – A Systematic Review.

Related Articles Patient-Reported Outcome Measures for Use in Clinical Trials and Clinical Practice in Inflammatory Bowel Diseases – A Systematic Review. Clin Gastroenterol Hepatol. 2017 Oct 23;: Authors: de Jong MJ, Huibregtse R, Masclee AAM, Jonkers DMAE, Pierik MJ Abstract BACKGROUND & AIMS: Mucosal inflammation must be carefully monitored to improve the long-term outcomes of patients with inflammatory bowel diseases (IBD). Patient-reported outcome measures (PROMs) are used increasingly to monitor disease activity in clinical practice and as endpoints in clinical trials. We performed a systematic review to provide an overview…

Read More

Non-Clostridium difficile Bacterial Infections Are Rare in Patients With Flares of Inflammatory Bowel Disease.

Related Articles Non-Clostridium difficile Bacterial Infections Are Rare in Patients With Flares of Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2017 Oct 13;: Authors: Hanada Y, Khanna S, Loftus EV, Raffals LE, Pardi DS Abstract BACKGROUND & AIMS: Clostridium difficile infection (CDI) causes flares in patients with inflammatory bowel disease (IBD). We investigated the frequency and outcomes of non-CDI bacterial enteric infections in symptomatic patients with IBD. METHODS: We performed a retrospective study of patients with ulcerative colitis (UC) or Crohn’s disease (CD) from whom stool samples were collected and analyzed…

Read More

Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn’s Disease in Sustained Remission.

Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn’s Disease in Sustained Remission. Clin Gastroenterol Hepatol. 2017 Oct 06;: Authors: Reenaers C, Mary JY, Nachury M, Bouhnik Y, Laharie D, Allez M, Fumery M, Amiot A, Savoye G, Altwegg R, Devos M, Malamut G, Bourreille A, Flourie B, Marteau P, Vuitton L, Coffin B, Viennot S, Lambert J, Colombel JF, Louis E, Groupe d’Etude Therapeutique des Affections Inflammatoires du tube Digestif (GETAID) Abstract BACKGROUND & AIMS: Little is known about long-term outcomes of patients with Crohn’s disease (CD) after…

Read More

Use of Biologic Therapy by Pregnant Women with Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines.

Related Articles Use of Biologic Therapy by Pregnant Women with Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. Clin Gastroenterol Hepatol. 2017 Sep 01;: Authors: Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U Abstract BACKGROUND & AIMS: In women with inflammatory bowel diseases (IBD), exposure to immunomodulator or biologic therapy has not been associated with adverse events during pregnancy or outcomes of newborns. We investigated whether exposure of patients to these agents during pregnancy affects serologic responses to vaccines in newborns. METHODS: We collected…

Read More

A Systematic Review for the Development of a Core Outcome Set for Ulcerative Colitis Clinical Trials.

A Systematic Review for the Development of a Core Outcome Set for Ulcerative Colitis Clinical Trials. Clin Gastroenterol Hepatol. 2017 Aug 23;: Authors: Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, D’Haens G, Sandborn WJ, Feagan BG, Jairath V Abstract BACKGROUND AND AIMS: Advances in drug development for ulcerative colitis (UC) have been paralleled by innovations in trial design. Development of a core outcome set (COS) to standardize outcome definitions and reporting in clinical trials is desirable. We aim to systematically review…

Read More
<< Go Back